GMP Inspection Readiness: How to Prepare Your Site for FDA, EMA and MHRA Visits

What Health Authority Inspectors Are Looking For

FDA, EMA and MHRA inspectors share a common objective: to verify that your quality management system is functioning as designed, that your products are manufactured and controlled as described in your regulatory submissions, and that you have a culture of quality that drives continuous improvement rather than compliance management. The specific evidence they seek differs by jurisdiction — FDA is particularly focused on data integrity and CAPA effectiveness, EMA on pharmaceutical quality system maturity, MHRA on risk-based quality management — but the underlying assessment framework is consistent.

The inspectors who conduct unannounced or announced inspections at pharmaceutical and medical device manufacturing sites have typically conducted dozens or hundreds of inspections. They recognise the difference between a site that has been prepared for this specific inspection and a site whose quality systems function continuously at an inspection-ready standard. The preparation that creates the latter — not the former — is what this guide addresses.

The Twelve Weeks Before Inspection

If your inspection date is known, twelve weeks is sufficient time to close the gaps that most commonly generate observations — provided the preparation is systematic and prioritised by risk rather than by administrative convenience. If the inspection is unannounced — which is increasingly the case for FDA — your site must be at inspection readiness standard continuously, not on a twelve-week preparation cycle.